checkAd
    Startseite > Aktien > Gain Therapeutics > Nachrichten
    Gain Therapeutics Aktie
    2,6300
     
    USD
    -2,23 %
    -0,0600 USD
    Letzter Kurs 17.05.24 Nasdaq
    2,5900
     
    USD
    2.400 STK
    Geldkurs 17.05.24
    2,6300
     
    USD
    500 STK
    Briefkurs 17.05.24
    ISIN: US36269B1052 · WKN: A2QQZ4 · SYM: GANX · USA

    Neueste Nachrichten

    Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
    14.05.24 · globenewswire · Gain Therapeutics
    Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
    24.04.24 · globenewswire · Gain Therapeutics
    Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
    08.04.24 · globenewswire · Gain Therapeutics
    Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
    01.04.24 · globenewswire · Gain Therapeutics
    Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
    26.03.24 · globenewswire · Gain Therapeutics
    Gain Therapeutics to Present at Public Ventures Discovery Day
    15.03.24 · globenewswire · Gain Therapeutics
    Gain Therapeutics Presents Data at the AD/PD 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
    05.03.24 · globenewswire · Gain Therapeutics
    Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
    27.02.24 · globenewswire · Gain Therapeutics
    Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
    14.02.24 · globenewswire · Gain Therapeutics
    UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
    06.02.24 · globenewswire · Gain Therapeutics
    Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
    06.02.24 · globenewswire · Gain Therapeutics
    Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update
    31.01.24 · globenewswire · Gain Therapeutics